In this study, we found that ER expression, HER2 IHC 3+ status, and high TIL levels were independent predictors of high pCR rates in patients with HER2-positive breast cancer who underwent neoadjuvant TCHP. The gene discussed is ESR1; the disease is breast carcinoma.